Amicus Therapeutics Inc FOLD
$14.49 $0.03 (0.21%) 1D
Last Updated: Apr 24, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
FOLD Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Amicus Therapeutics Inc is classified as halal.
HALAL
Report Source: undefined Quarter Report
Amicus Therapeutics Inc. Stock Analysis FOLD
United States Health Care Mid Cap Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. The company is headquartered in Princeton, New Jersey and currently employs 511 full-time employees. The company went IPO on 2007-05-31. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Amicus Therapeutics Inc (FOLD) Chart
Financial Metrics & Statements of Amicus Therapeutics Inc (FOLD)
FAQ's for Amicus Therapeutics Inc (FOLD)
- As of August 2026, Amicus Therapeutics Inc FOLD is classified as halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Amicus Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Amicus Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Amicus Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Amicus Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Amicus Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Related Halal Stocks to Amicus Therapeutics Inc (FOLD)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
